Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

BACKGROUND & AIMS: Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that gemcitabine plus S‐1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Nai‐Jung, Chen, Ming‐Huang, Yang, Shih‐Hung, Hsu, Chiun, Yen, Chia‐Jui, Tsou, Hsiao‐Hui, Su, Yung‐Yeh, Chen, Jen‐Shi, Shan, Yan‐Shen, Chen, Li‐Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540301/
https://www.ncbi.nlm.nih.gov/pubmed/32463975
http://dx.doi.org/10.1111/liv.14538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540301/
https://www.ncbi.nlm.nih.gov/pubmed/32463975
http://dx.doi.org/10.1111/liv.14538

Ejemplares similares